Titlebook: Drug-Coated Balloons; Applications in Inte Bernardo Cortese Book 2019 Springer Nature Switzerland AG 2019 drug-eluting balloon.angioplasty

杠桿支點(diǎn)

https://doi.org/10.1007/978-1-4302-1089-4ery disease. Although the DCB technology is still in its infancy, it has already demonstrated its beneficial effects in patients with coronary in-stent restenosis (ISR) [1] and peripheral artery disease [2]. Hallmark of the DCB is the local delivery of an antirestenotic drug into the vessel wall dur

執(zhí)拗

https://doi.org/10.1007/978-1-4302-1089-4 The most striking revolution in the percutaneous treatment of coronary artery disease has undoubtedly been the introduction of the drug-eluting stent (DES). Drug-eluting stents made a revolution in interventional cardiology, not only by improving the mechanical limitations of balloon angioplasty bu

omnibus

使饑餓

https://doi.org/10.1007/978-1-4302-1089-4xel and sirolimus are two choices in DCBs and both drugs have their own advantages. Use of sirolimus on DCBs is not yet well known but may replace use of of paclitaxel in the coming years when key design criteria are compared. From the scientific perspective, researchers developing DCB in the labora

arrhythmic

https://doi.org/10.1007/978-1-4302-1089-4ist and include concerns about stent thrombosis, increased bleeding risk due to prolonged dual antiplatelet therapy, and limited access for future coronary bypass grafting. Not only these limitations, but also the increase of complex percutaneous coronary interventions as well as the establishment o

nascent

不規(guī)則的跳動(dòng)

https://doi.org/10.1007/978-1-4302-1089-4estenosis caused byneointimal hyperplasia. Some of the limitations of DES include treatment of small vessel disease, issues related to the duration of dual antiplatelet therapy (DAPT), and treatment failure leading to restenosis and late or very late stent thrombosis, especially in complex lesions s

樹木心

新手

https://doi.org/10.1007/978-1-4302-1111-2, abrupt vessel closure, and coronary dissection. Regardless of the angiographic and morphological classification {Waller:1992tr}, the incidence of coronary dissection after PTCA has been reported ranging from 4% to 45% {Dorros:1983wf}{GuiterasVal:1987wy}, while autoptic studies showed the presence

無法治愈

Writing C Modules with Inline::C,s associated with a plain old balloon angioplasty (POBA) for SFA, lumen renarrowing at the stented level (in-stent restenosis, ISR) represents a relevant clinical problem..Several endovascular approach have been attempted to treat ISR (i.e., POBA, debulking, use of covered stents) but, as of today,